Vor Bio (Nasdaq: VOR) granted equity awards on June 1, 2026 to 10 newly hired employees under its 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards include stock options for 61,050 shares at $14.57 and RSUs for 12,900 shares, both vesting over four years.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
None.
Negative
None.
News Market Reaction – VOR
-6.25%
4 alerts
-6.25%News Effect
-$52MValuation Impact
$774.86MMarket Cap
0.1xRel. Volume
On the day this news was published, VOR declined 6.25%, reflecting a notable negative market reaction.
Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
This price movement removed approximately $52M from the company's valuation, bringing the market cap to $774.86M at that time.
Current share price:$14.57Stock options granted:61,050 optionsRSUs granted:12,900 RSUs+5 more
8 metrics
Current share price$14.57Closing price on June 1, 2026 (option grant exercise price)
Stock options granted61,050 optionsInducement awards to 10 newly hired employees
RSUs granted12,900 RSUsInducement awards to 10 newly hired employees
New hires10 employeesRecipients of inducement stock options and RSUs
Option exercise price$14.57 per shareEqual to Vor Bio’s closing price on the grant date
Option term10 yearsMaximum life of inducement stock options
Initial vesting cliff25% after 12 monthsApplies to both options and RSUs
Remaining vesting period36 monthsOptions vest monthly; RSUs vest quarterly thereafter
Market Reality Check
Price:$13.66Vol:Volume 533,213 vs 851,874...
low vol
$13.66Last Close
VolumeVolume 533,213 vs 851,874 20-day average indicates below-average trading activity.low
TechnicalShares at $14.57, trading below the $19.84 200-day moving average after a prolonged pullback from the $65.80 52-week high.
Peers on Argus
Momentum scanner shows biotech peers like ACIU and PRQR up over the session, whi...
2 Up
Momentum scanner shows biotech peers like ACIU and PRQR up over the session, while VOR’s move was modest and not flagged. Broader sector action appears mixed, suggesting this inducement grant news has a stock-specific character rather than driving or following a clear sector-wide move.
Common CatalystAnother peer, CADL, also reported inducement grants under Nasdaq Listing Rule 5635(c)(4), pointing to ongoing talent-related equity awards across the group.
Inducement stock options and RSUs granted to nine new employees.
Pattern Detected
Recent news often saw negative price reactions, even to positive or neutral items, with only prior inducement grants coinciding with gains.
Recent Company History
Over the last few months, Vor Bio released multiple updates, including conference participation on Jun 3, 2026, positive Phase 3 TELIGAN data in IgA nephropathy, and Q1 2026 financials highlighting a larger net loss but substantial cash runway. The company has also repeatedly used inducement grants under its 2023 Inducement Plan, with awards on Apr 1 and May 1, 2026. Those prior inducement announcements coincided with single-day gains, contrasting with declines following clinical and financial updates.
Regulatory & Risk Context
Active S-3 Shelf
Shelf Active
Active S-3 Shelf Registration
2026-04-27
An effective S-3 shelf dated Apr 27, 2026 registers up to 5,338,078 shares for resale from a March 2026 private placement at $14.05 per share, with Vor Bio receiving no proceeds from these resales. This structure primarily facilitates liquidity for existing holders rather than new primary capital issuance.
Market Pulse Summary
The stock moved -6.3% in the session following this news. A negative reaction despite this routine i...
Analysis
The stock moved -6.3% in the session following this news. A negative reaction despite this routine inducement grant would fit a pattern where even neutral or positive headlines, such as conference participation and strong Phase 3 data, previously saw declines of over 3%. The awards (options on 61,050 shares and 12,900 RSUs) add modest stock-based compensation over four years. Any sharp downside might therefore reflect broader concerns around past losses and capital structure, rather than this administrative equity action alone.
"granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock optionsfinancial
"granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
inducement planfinancial
"were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”)"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.
exercise pricefinancial
"an exercise price of $14.57 per share, which is equal to the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"The options will vest over a four-year period, with 25% of the shares vesting after 12 months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
The stock options have a ten-year term, and an exercise price of $14.57 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employees’ continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
FAQ
What equity awards did Vor Bio (NASDAQ: VOR) grant on June 1, 2026?
Vor Bio granted stock options for 61,050 shares and RSUs for 12,900 shares to 10 new employees. According to Vor Bio, these inducement awards were issued under the 2023 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and term of the new Vor Bio (VOR) stock options?
The new Vor Bio stock options have a ten-year term and an exercise price of $14.57 per share. According to Vor Bio, this price equals the closing price of its common stock on the June 1, 2026 grant date.
How do Vor Bio’s June 2026 inducement stock options (VOR) vest for new employees?
Vor Bio’s inducement stock options vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the next 36 months. According to Vor Bio, vesting requires continued employment on each vesting date.
How do the Vor Bio (VOR) RSUs granted on June 1, 2026 vest?
The RSUs vest over four years, with 25% of shares vesting after 12 months and the rest vesting quarterly over the following 36 months. According to Vor Bio, vesting is conditioned on continued employment throughout the schedule.
Under which plan were Vor Bio’s June 2026 inducement grants (VOR) issued?
The June 1, 2026 stock option and RSU inducement grants were issued under the Vor Biopharma 2023 Inducement Plan. According to Vor Bio, these awards are subject to the plan’s terms and the related award agreements.
Why were Vor Bio (VOR) inducement equity awards granted to 10 new employees?
The equity awards were granted as material inducements to employment for 10 newly hired employees. According to Vor Bio, this approach complies with Nasdaq Listing Rule 5635(c)(4) and uses the company’s 2023 Inducement Plan for the grants.
